Biogen to Acquire Nightstar Therapeutics for $800M

Shots: Biogen acquires Nightstar Therapeutics, in all stock transaction with its lead candidates NSR-REP1 & NSR-RPGR. Nightstar Therapeutics to receive $25.50 /share in cash for one day premium of 68% on closing of $15.16 making the total deal value $800M The focus of an acquisition is to strengthen Biogen’s portfolio in ophthalmology. Biogen expected to […]Read More